Skip to content

EULAR 2025: rheumatoid arthritis

International EULAR Current

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2025 update

Smolen JS, et al. Ann Rheum Dis. 2026;85:991–1009
DOI 10.1016/j.ard.2026.01.023 · Summary checked against the source: 2026-11

Read or download the original

5 overarching principles and 9 recommendations, down from 11 in 2022. Citations give the level of evidence and strength of recommendation as written in the guideline.

At a glance

  1. Start a DMARD as soon as RA is diagnosed. [1a/A · p. 995]
  2. Treat to target: sustained remission, or low disease activity. [1a/A · p. 995]
  3. Methotrexate first, with short-term glucocorticoids tapered and stopped quickly. If MTX is contraindicated: leflunomide or sulfasalazine. [1a/A · p. 995]
  4. Review: improvement by 3 months, target by 6 months, or change therapy. [2b/B · p. 995]
  5. Biggest change: if the MTX strategy fails, add a biologic for everyone. Prognostic stratification is gone, and a second csDMARD round is no longer the standard next step. JAK inhibitors only after a risk assessment. [1a/A · p. 995, 999]
  6. Sustained remission off steroids: continue DMARDs, but dose reduction may be considered. [1b/A · p. 995]

Overarching principles

  • A. Best care through shared decision-making between patient and rheumatologist.
  • B. Decisions rest on disease activity, safety, comorbidities and structural damage.
  • C. Rheumatologists should primarily care for people with RA.
  • D. Patients need access to drugs with different modes of action, and may need several over a lifetime.
  • E. RA has high individual, medical and societal costs, which should be considered.

Adapted from EULAR 2025 Table 1 [p. 995]

Recommendations

# Recommendation LoE/SoR
1 Start DMARDs as soon as RA is diagnosed 1a/A
2 Target sustained remission or low disease activity in every patient 1a/A
3 Monitor every 1–3 months in active disease. No improvement by 3 months or target not reached by 6 months: adjust therapy 2b/B; 5/D
4 MTX in the first strategy. Contraindication or early intolerance: leflunomide or sulfasalazine 1a/A
5 Short-term glucocorticoids when starting or changing csDMARDs, tapered and stopped as fast as possible 1a/A
6 Target not reached on csDMARDs: add a bDMARD; JAK inhibitors may be considered after weighing risk factors 1a/A (efficacy), 2a/B (safety)
7 Combine b/tsDMARDs with a csDMARD. If no csDMARD can be used, IL-6 inhibitors and JAK inhibitors have some advantages 1a/A
8 b/tsDMARD failure: another bDMARD or tsDMARD. After one TNF or IL-6R inhibitor fails, use another mode of action or a second agent of the same class 1a/A; 5/D; 3/C
9 Sustained remission after stopping steroids: continue DMARDs; dose reduction (or longer intervals) may be considered 1b/A

Adapted from EULAR 2025 Table 1 [p. 995]

Treatment algorithm

flowchart TD
    A["Clinical diagnosis of RA<br/>(2010 ACR/EULAR criteria support early diagnosis)"] -->|No contraindication| M["Start methotrexate"]
    A -->|Contraindication to MTX| L["Start leflunomide or sulfasalazine"]
    M --> G["Plus short-term glucocorticoids<br/>(reduce and stop as rapidly as possible)"]
    L --> G
    G --> Q1{"Improved at 3 months and<br/>target reached at 6 months?"}
    Q1 -->|Yes| C1["Continue → dose reduction<br/>in sustained remission"]
    Q1 -->|No| P2["Phase II: add a bDMARD<br/>JAK inhibitor only after risk assessment"]
    P2 --> Q2{"Improved at 3 months and<br/>target reached at 6 months?"}
    Q2 -->|Yes| C2["Continue → dose reduction or<br/>interval increase in sustained remission"]
    Q2 -->|No| P3["Phase III: change the bDMARD<br/>or JAK inhibitor"]
    P3 --> Q3{"Improved at 3 months and<br/>target reached at 6 months?"}
    Q3 -->|Yes| C3["Continue → dose reduction or<br/>interval increase in sustained remission"]
    Q3 -->|No| P3
Adapted from EULAR 2025 algorithm figure [p. 1001]

Notes from the figure

  • Target: clinical remission by ACR/EULAR definitions; if unlikely, at least low disease activity. Expect ≥50% improvement by 3 months. Sustained remission = ≥6 months in ACR/EULAR index-based (CDAI/SDAI) or Boolean remission.
  • MTX combinations: starting with MTX doesn't exclude combining it with other csDMARDs (the usual combination is MTX + sulfasalazine + hydroxychloroquine), but they add adverse events without added benefit. Leflunomide or sulfasalazine may be an interim step if MTX isn't enough before adding a bDMARD or JAKi.
  • bDMARDs: TNF inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), abatacept, IL-6R inhibitors, or rituximab (under certain conditions), and EMA/FDA-approved biosimilars.
  • Risk factors to weigh before a JAK inhibitor: age over 65, current or past smoking, other CV risk factors (diabetes, obesity, hypertension), malignancy risk (current or previous cancer other than treated non-melanoma skin cancer), VTE risk (previous MI or heart failure, cancer, inherited clotting disorder or previous clots, combined hormonal contraception or HRT, major surgery, immobility).
  • Tapering: reduce dose or lengthen intervals for bDMARDs and JAKi; stopping completely brings a high flare rate. Stop glucocorticoids before tapering DMARDs.

Adapted from EULAR 2025 algorithm footnotes [p. 1001]

Clinical pearls

  • Anchor drug: methotrexate, with folic acid. Leflunomide or sulfasalazine if it can't be used.
  • Treat to target, review every 1–3 months; change if no response at 3 months or not at target by 6.
  • After MTX failure, add a biologic (2025 change). JAK inhibitors carry MACE, malignancy and VTE warnings (ORAL Surveillance).
  • Monotherapy without a csDMARD: IL-6 inhibitors (tocilizumab, sarilumab) or JAK inhibitors work best.
  • Taper in remission, steroids first; don't stop DMARDs completely.

Classes and levels of evidence

How EULAR 2025 grades its recommendations. Adapted from EULAR 2025 Table 1 (Oxford levels) [p. 995]. Hover over any class or level cited on this page to see what it means.

LoE Meaning Wording used
LoE 1a Systematic review of RCTs
LoE 1b Individual RCT
LoE 2a Systematic review of cohort studies
LoE 2b Individual cohort study, or a low-quality RCT
LoE 3a Systematic review of case-control studies
LoE 3b Individual case-control study
LoE 4 Case series, or poor-quality cohort or case-control studies
LoE 5 Expert opinion
Level Meaning
GoR A Based on consistent level 1 studies
GoR B Based on consistent level 2 or 3 studies, or extrapolated from level 1
GoR C Based on level 4 studies, or extrapolated from level 2 or 3
GoR D Based on level 5 evidence, or troublingly inconsistent or inconclusive studies

EULAR tags each recommendation with a level of evidence (LoE, 1a–5) and a grade of recommendation (GoR, A–D) from the Oxford Centre for Evidence-Based Medicine, written as "1b/A". Overarching principles carry no LoE. Each statement also has a level of agreement: the panel's mean score from 0 to 10.